已传文件：photo/1773121782.png
Psoriasis is a chronic inflammatory skin disease driven by oxidative stress, and it requires advanced antioxidant nanoenzymes capable of eliminating broad-spectrum reactive oxygen species (ROS). This study addresses this challenge by rationally designing a ternary synergistic nanocluster, Ag14–20 Au5–11 @FeTP. This cluster is engineered through "atomic engineering" to achieve the optimal AgAu alloy core, and through molecular engineering, it is realized through Fe-porphyrin ligand grafting. This dual-energy-level engineering creates a metal-ligand cooperative interface, endowing it with outstanding multi-enzyme mimetic activity for the removal of H2O2, •O2−, and •OH. Combined with enhanced skin penetration, this nanoenzyme demonstrates therapeutic and preventive effects in a psoriasis mouse model, comparable to the first-line clinical drug betamethasone/dihydroxyvitamin D3, and without significant systemic toxicity. Transcriptomic analysis reveals that its potency stems from two pathways of immune regulation: simultaneously inhibiting the pro-inflammatory IL-23/Th17/IL-17 and NF-κB axes, and enhancing the anti-inflammatory Treg/Th2 pathways. This study establishes a scalable "precision synergy" paradigm for designing high-performance nanocluster therapies targeting oxidative stress-related inflammatory diseases. This research was published under the title "Ternary Synergy in an Atomically Precise Alloy Nanocluster: Precision Engineering of a ROS-Suppressing Nanozyme for Effective Psoriasis Therapy" in Advanced Functional Materials.
References:
DOI: 10.1002/adfm.7547
